Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring Americans to understand their relationship with sleep

Jennifer Aniston partners with Idorsia US to launch the “Seize the Night & Day” campaign that inspires Americans to understand their relationship with sleep

  • Jennifer reveals for the first time her sleep story, spanning many years of challenges and how she learned to make sleep a priority in order to have both better nights and better days

  • The national education campaign is a beacon of hope by shedding light on the approximately 25 million US adults living with insomnia

  • The campaign provides educational resources to help people and healthcare providers understand the dual effects of insomnia, affecting both nights and days

Allschwil, Switzerland & Radnor, PA, USAJanuary 12th, 2022
Idorsia Ltd (SIX: IDIA) and Idorsia Pharmaceuticals, US Inc. today announced their partnership with award-winning actress and director / producer Jennifer Aniston to launch Seize the Night & Day, an integrated awareness campaign aimed at delivering the dual impact of uncovering insomnia that affects both nights and days. The national initiative sheds light on the reality of insomnia for the millions of Americans living with this very real, but often overlooked, condition. Idorsia and Jen have forged a multi-year collaboration with the common goal of informing, inspiring, and empowering people to take the first steps toward quality sleep through education, actionable information, and community support.

Jen tells her very own personal sleep story for the first time and the effect that sleep problems had on her nights and days. Their goal is to help those who are not getting the quality of sleep they deserve better understand that they are not alone when it comes to insomnia.

Sleep, diet and physical activity are the three pillars of health. Sleep is often overshadowed by diet and exercise, but its effects on people are becoming better understood. Insomnia is the most common sleep disorder in the United States, affecting approximately 25 million adults.1 A lack of good quality sleep can affect people’s daily life, including concentration, mood, and energy levels.2 In the long term, insomnia is linked to an increased risk of numerous serious health conditions such as psychiatric illnesses, cardiovascular diseases, type 2 diabetes, substance abuse and dementia.3, 4, 5

Jennifer Aniston commented:
“My challenges with sleeping began many years ago – that’s why it’s such a high priority for my overall health. If I don’t sleep well, my next day is really difficult. By working with Idorsia, I hope we can all begin to prioritize sleep health and have different conversations about sleep issues. “

Visit “Seize the Night & Day” to learn more about Jen’s sleep story.

As part of the campaign, Jen will be featured in digital and television commercials bringing to life how people are not themselves when they are not getting a good night’s sleep. In addition, the campaign provides online educational resources that explore the science behind insomnia and its dual effects, affecting both nights and days; Tips for getting a better night’s sleep and a sleep routine; and a community forum where people can connect with others to share positive sleep affirmations.

Patricia Torr, President and General Manager of Idorsia US commented:
“Seize the Night & Day exemplifies Idorsia’s commitment to providing people with insomnia with the information they need to take the first step towards improving their sleep. Jen is a natural partner for the campaign as she has had trouble sleeping for many years. We share a common vision to help others understand how the dual effects of insomnia affect both nights and days and the importance of a good night’s sleep. “

Learn more about it #Seize the night and the day Visit the consumer and handicap websites and keep track of the conversation Twitter, Facebook, Instagram and LinkedIn.

Notes to the editors

About Jen Aniston’s sleep story
Jen Aniston has had sleep problems for nearly 20 years and knows firsthand the importance of making sleep health a priority. Over the years she has learned the importance of good sleep and good sleeping habits. Jen wants to inspire others who have insomnia to make their sleep health a priority and encourage them to learn about how insomnia can affect not only their nights but also their days. Most of all, she wants people to remember that they are not alone. Through Seize the Night & Day, Jen is able to provide those with sleep problems with the educational resources and tools they need to ensure they too have rested nights and refreshed days.

About insomnia
Insomnia is defined as a combination of difficulty getting enough sleep and dissatisfaction with sleep, with a significant negative impact on daytime function. Insomnia is defined as the difficulty in initiating and / or maintaining sleep for at least three nights a week for at least three months in spite of adequate sleep.

Insomnia is a state of overactive brain activity during sleep, and studies have shown that areas of the brain associated with wakefulness remain more active during sleep in patients with insomnia.

Significant insomnia is a common problem, with a prevalence of around 10%. On this basis, and assuming an adult US population of approximately 250 million, approximately 25 million adults in the US are living with insomnia.

Insomnia as a chronic condition is different from a short period of poor sleep and can be both physical and mental. It can be a persistent condition with a negative impact on daily function. Research from Idorsia has shown that poor quality sleep can affect many aspects of daily life, including concentration, mood, and energy levels.

The goals of insomnia treatment are to improve the quality and quantity of sleep and daily function. The currently recommended treatments for insomnia include recommendations for sleep hygiene, cognitive behavioral therapy, and pharmacotherapy.

References

  1. Bhaskar S, Hemavathy D, Prasad S. Prevalence of chronic insomnia in adult patients and its correlation with medical comorbidities. J Family Med Prim Care. 2016; 5 (4): 780-784. doi: 10.4103 / 2249-4863.201153.

  2. Ustinov Y, Lichtstein KL, Wal GS, Taylor DJ, Riedel BW, Bush AJ. Association between reports of insomnia and diurnal function. Sleep Med. 2010 Jan; 11 (1): 65-8. doi: 10.1016 / j.sleep.2009.07.009. Epub 2009 09/23

  3. Olfson M, Wall M, Liu SM, Morin CM, Blanco C. Insomnia and impaired quality of life in the United States. J Clin Psychiatry. 2018 Sep 11; 79 (5): 17m12020. doi: 10.4088 / JCP.17m12020.

  4. Doghramji K. The epidemiology and diagnosis of insomnia. Am J Manag Care. 2006 May; 12 (8 Suppl): S214-20. PMID: 16686591.

  5. de Almondes KM, Costa MV, Malloy-Diniz LF, Diniz BS. Insomnia and risk of dementia in older adults: systematic review and meta-analysis. J Psychiatrist Res. June 2016; 77: 109-15. doi: 10.1016 / j.jpsychires.2016.02.021. Epub 2016 Mar 8. PMID: 27017287.

About Idorsia USA
Idorsia US, an Idorsia subsidiary, strives for more – we have more ideas, we see more opportunities and we want to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company with a strong scientific core. With commercial operations outside of Philadelphia, PA, one of the world’s densest communities of life science talent, we help achieve the company’s goal of bringing innovative drugs from the lab to the bedside. Our goal is to build a commercial presence that will bring Idorsia’s extensive product pipeline from its R&D engine to the US market – with the potential to change the lives of many patients.

About Idorsia
Idorsia Ltd strives for more – we have more ideas, we see more opportunities and we want to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia specializes in the discovery, development and commercialization of small molecules to change the horizons of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals spanning all disciplines from the laboratory to the bedside, state-of-the-art facilities and a strong track record – the ideal combination to turn R&D efforts into business success.

Idorsia was listed on the SIX Swiss Exchange in June 2017 (ticker symbol: IDIA) and employs over 1,000 highly qualified specialists who are dedicated to realizing our ambitious goals.

For more information please contact

US media
Christopher Clark
Senior Director, US Head of Communications
Idorsia Pharmaceuticals USA, 100 Matsonford Road, Radnor, PA 19087
+1 (215) 421 4887
christopher.clark@idorsia.com
www.idorsia.us

Global Investors & Media
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharma AG, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com

The above information contains certain “forward-looking statements” relating to the company’s business that can be identified by using forward-looking terminology such as “estimates,” “believes,” “expects,” “may,” “is,” expects, “will”, “continuing”, “should”, “should”, “aiming”, “forthcoming” or “anticipated” or similar expressions, or through discussions of strategy, plans or intentions. Such statements include descriptions of the Company’s investment and research and development programs and associated anticipated expenses, descriptions of new products expected to be introduced by the Company, and expected customer demand for such products and products in the Company’s existing portfolio. Such statements reflect the company’s current views with respect to future events and are subject to risks, uncertainties and assumptions. Many factors could cause actual results, performance, or accomplishments of the company to differ materially from future results, performance or accomplishments expressed or implied in such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results could differ materially from the expected, assumed, estimated or expected results described herein.

Appendix

Leave a Comment

Your email address will not be published. Required fields are marked *